Patient Group Direction for COVID-19 mRNA vaccine BNT162b2 (Pfizer/BioNTech)

Document first published:
Page updated:
Topic:
Publication type:

This Patient Group Direction (PGD) is for the administration of COVID-19 mRNA vaccine BNT162b2 30micrograms in 0.3ml to individuals in accordance with the national COVID-19 vaccination programme. Current versions of PHE/UKHSA developed COVID-19 vaccine PGDs can be found via: COVID-19 vaccination programme

 

Summary

Providers must check that they are using the current version of the PGD. Amendments may become necessary prior to the published expiry date.

Published 11 December 2020. Updated 19 November 2021.

Summary

Word version of this Patient Group Direction.

Published 11 December 2020. Updated 19 November 2021.